Connect with us
  • Elysium


Daily News Round Up: Tuesday, 2 July

Welcome to your daily round-up of everything happening in the world of neurorehabilitation.

Research news

Finding the sweet spot in brain development



Welcome to your daily round-up of everything happening in the world of neurorehabilitation.

Research news

Finding the sweet spot in brain development

Cold Spring Harbor Laboratory Assistant Professor Gabrielle Pouchelon studies how the brain is wired early in life. In doing so, she hopes to find the origins of various brain dysfunctions and new ways to treat them. In a new study, her team have zeroed in on a process known as pruning. This is when the brain removes unnecessary connections between neurons. The pruning of long-lasting connections is relatively well-known. Pouchelon’s team focuses on special early connections that get cut to make way for long-lasting circuits in the mature brain. Though temporary, these early connections may play a critical role in shaping developing brain circuits.

Advancement in modulation of brain extracellular space and unlocking its potential for intervention of neurological diseases

Cells in the brain are surrounded by extracellular space (ECS), which forms porous nets and interconnected routes for molecule transportation. Our view of brain ECS has changed from a largely static compartment to dynamic and diverse structures that actively regulate neural activity and brain states. Emerging evidence supports that dysregulation of brain ECS contributes to the pathogenesis and development of many neurological disorders, highlighting the importance of therapeutic modulation of brain ECS function.

The team led by Fenfang Li from Institute of Biomedical Engineering, Shenzhen Bay Laboratory, provide an overview of the regulation and dysfunction of ECS in healthy and pathological brains, as well as advanced tools to investigate properties of brain ECS. This review emphasizes modulation methods to manipulate ECS with implications to restore their function in brain diseases.

Company and financial neuro-rehab news

NeuroSense demonstrates statistically significant efficacy and survival benefits in ALS

NeuroSense Therapeutics has reported statistically significant results from the 12-month data analysis of the PARADIGM Phase 2b study evaluating PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS).

The data show a significant improvement in the rate of decline of ALS Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for subjects who received PrimeC from the start of the trial compared to those who started on placebo. Specifically, the intent to treat (ITT) analysis of the study at 12 months revealed a difference of 6.5 points in the ALSFRS-R, which represents a 36% improvement and a highly statistically significant P value of 0.009.

In addition, at 12 months participants on PrimeC demonstrated better survival than those initially on placebo, by 43%.

Neurotechnology news

Prosthetic legs controlled by person’s own neural system bring natural gait

U.S News reports that an experimental surgical procedure combined with a cutting-edge robotic limb can restore a completely natural walking gait, fully driven by a person’s own nervous system.